Sana Biotechnology, INC Form 4 insider transactions

Sana Biotechnology Director Hans Edgar Bishop reported the vesting of 6,297 restricted stock units on July 6, 2026.

Director Patrick Y. Yang was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Director Robert L. Rosiello was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity incentive.

Director Alise Reicin was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Director Richard Mulligan was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity incentive.

Director Hans Edgar Bishop was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Director Joshua H. Bilenker was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity compensation arrangement.

Director Robert Nelsen was granted 90,000 stock options in Sana Biotechnology, Inc. with an exercise price of $2.96.

Sana Biotechnology Director Hans Edgar Bishop reported the vesting of 7,763 restricted stock units on April 6, 2026.

Sana Biotechnology, Inc. disclosed new equity grants, including restricted stock units and stock options, to Susan D. Wyrick, SVP of Finance and Accounting.

Sana Biotechnology's President and CEO, Steve Harr, was granted 200,000 Restricted Stock Units and 900,000 stock options, aligning his incentives with long-term company performance.

Sana Biotechnology's SVP of Finance and Accounting, Susan D. Wyrick, reported the conversion of restricted stock units and subsequent sale of shares to cover tax obligations.

Sana Biotechnology's Acting CFO, Susan D. Wyrick, converted 7,500 restricted stock units into common stock and subsequently sold 2,407 shares to cover tax obligations.

Sana Biotechnology, Inc. Director Hans Edgar Bishop reported the acquisition of 6,157 shares of common stock through vested restricted stock units.

Sana Biotechnology's Acting CFO, Susan D. Wyrick, reported the vesting of 3,400 restricted stock units and the subsequent sale of 873 shares for tax withholding.

Sana Biotechnology's Acting CFO, Susan D. Wyrick, reported routine equity transactions including RSU vesting, option grants, and share dispositions for tax withholding.

Sana Biotechnology Director Hans Edgar Bishop acquired 5,628 shares of common stock, increasing his total beneficial ownership to 5,834,583 shares.

Sana Biotechnology, Inc. Director Hans Edgar Bishop reported the acquisition of 7,842 shares of common stock through fully vested restricted stock units, increasing his beneficial ownership to over 5.8 million shares.

Sana Biotechnology, Inc. Director Robert L. Rosiello was granted 115,000 stock options with an exercise price of $2.55, vesting over 36 months, as reported in a recent SEC Form 4 filing.

Sana Biotechnology, Inc. Director Joshua H. Bilenker has acquired 80,000 stock options with an exercise price of $2.55, signaling potential confidence in the company's future.

Sana Biotechnology, Inc. Director Hans Edgar Bishop was granted 80,000 stock options with an exercise price of $2.55, aligning his interests with long-term shareholder value.

Sana Biotechnology, Inc. has reported that Director Richard Mulligan was granted 80,000 stock options with an exercise price of $2.55, vesting by June 2026.

Sana Biotechnology, Inc. (SANA) Director Alise Reicin has been granted 80,000 stock options, aligning her interests with shareholder value.

Sana Biotechnology, Inc. Director and 10% owner Robert Nelsen was granted 80,000 stock options with an exercise price of $2.55, vesting in 2026.

Sana Biotechnology, Inc. (SANA) director Michelle Seitz has been granted 80,000 stock options with an exercise price of $2.55, aligning her interests with shareholder value.

Sana Biotechnology, Inc. Director Mary Agnes Wilderotter was granted 80,000 stock options with an exercise price of $2.55, vesting by June 2026.

Sana Biotechnology, Inc. Director Patrick Y. Yang reported the acquisition of 80,000 stock options with an exercise price of $2.55, vesting by June 2026.

Director Hans Edgar Bishop reports acquiring 16,339 shares of Sana Biotechnology common stock through fully vested restricted stock units.

Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, reports acquisition and disposal of common stock and derivative securities.

Bernard J. Cassidy, EVP & General Counsel of Sana Biotechnology, reports acquisition and disposal of common stock and derivative securities.